微创与开放远端胰腺切除术治疗胰腺导管腺癌(DIPLOMA)随机对照试验研究方案
DIPLOMA是一项国际随机对照、患者和病理学家盲法、非劣效性试验,在欧美38个胰腺中心纳入258例拟行择期远端胰腺切除联合脾切除的胰腺体尾部PDAC患者,1:1随机分配至MIDP或ODP。主要结局为显微镜下根治性切缘(R0,肿瘤距胰腺切缘及后切缘≥1 mm)。
要点
- MIDP对比ODP治疗PDAC,主要终点R0切除率采用非劣效设计,非劣效界值7%。
- 样本量基于开放组R0率58%、微创组67%、单侧α=5%、把握度80%计算为258例。
- 次要结局涵盖功能恢复时间、手术结局、病理、术后并发症、复发、生存、生活质量和费用。
核心结论
- DIPLOMA试验旨在国际多中心背景下验证MIDP对比ODP治疗PDAC在显微镜下根治性切除率上的非劣效性。
研究设计与样本
- 国际随机对照、患者和病理学家盲法、非劣效性试验,在欧美38个胰腺中心开展。
- 计划纳入258例因确诊或高度怀疑胰腺体尾部PDAC而拟行择期远端胰腺切除联合脾切除的患者,1:1随机分配至MIDP(腹腔镜或机器人辅助)或ODP。
- 主要结局R0采用标准化组织病理学评估方案判定,R0定义为肿瘤距胰腺切缘和后切缘≥1 mm。
关键数值与推荐
- 样本量计算假设:单侧显著性水平5%(α)、把握度80%(1-β)、开放组预期R0率58%、微创组预期R0率67%、非劣效界值7%。
- 主要结局为显微镜下根治性切缘(R0,肿瘤距胰腺切缘和后切缘≥1 mm)。
- 随访在术后6、12、18、24和36个月于门诊进行。
临床怎么用
- 该试验结果将为PDAC患者选择微创或开放远端胰腺切除术的肿瘤学安全性提供随机对照证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Recently, the first randomized trials comparing minimally invasive distal pancreatectomy (MIDP) with open distal pancreatectomy (ODP) for non-malignant and malignant disease showed a 2-day reduction in time to functional recovery after MIDP. However, for pancreatic ductal adenocarcinoma (PDAC), concerns have been raised regarding the oncologic safety (i.e., radical resection, lymph node retrieval, and survival) of MIDP, as compared to ODP. Therefore, a randomized controlled trial comparing MIDP and ODP in PDAC regarding oncological safety is warranted. We hypothesize that the microscopically radical resection (R0) rate is non-inferior for MIDP, as compared to ODP. METHODS/DESIGN: DIPLOMA is an international randomized controlled, patient- and pathologist-blinded, non-inferiority trial performed in 38 pancreatic centers in Europe and the USA. A total of 258 patients with an indication for elective distal pancreatectomy with splenectomy because of proven or highly suspected PDAC of the pancreatic body or tail will be randomly allocated to MIDP (laparoscopic or robot-assisted) or ODP in a 1:1 ratio. The primary outcome is the microscopically radical resection margin (R0, distance tumor to pancreatic transection and posterior margin ≥ 1 mm), which is assessed using a standardized histopathology assessment protocol. The sample size is calculated with the following assumptions: 5% one-sided significance level (α), 80% power (1-β), expected R0 rate in the open group of 58%, expected R0 resection rate in the minimally invasive group of 67%, and a non-inferiority margin of 7%. Secondary outcomes include time to functional recovery, operative outcomes (e.g., blood loss, operative time, and conversion to open surgery), other histopathology findings (e.g., lymph node retrieval, perineural- and lymphovascular invasion), postoperative outcomes (e.g., clinically relevant complications, hospital stay, and administration of adjuvant treatment), time and site of disease recurrence, survival, quality of life, and costs. Follow-up will be performed at the outpatient clinic after 6, 12, 18, 24, and 36 months postoperatively. DISCUSSION: The DIPLOMA trial is designed to investigate the non-inferiority of MIDP versus ODP regarding the microscopically radical resection rate of PDAC in an international setting. TRIAL REGISTRATION: ISRCTN registry ISRCTN44897265 . Prospectively registered on 16 April 2018.
引用
- van Hilst J, Korrel M, Lof S, et al. Minimally invasive versus open distal pancreatectomy for pancreatic ductal adenocarcinoma (DIPLOMA): study protocol for a randomized controlled trial. Trials. 2021. PMID: 34503548. doi:10.1186/s13063-021-05506-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。